Objective(s): Program death 1 (PD-1)/ program death-ligand 1 (PD-L1) pathways, as the main inhibitory checkpoints, induce immunosuppression in the tumor microenvironment (TME). Despite the importance of inhibitor checkpoint receptor (ICR) blockers, their outcomes have been limited by the low immune response rate and induced acquired resistance. Pre-existing tumor-speci...

parkinson`s disease (pd) is the second most common neurodegenerative disorder after alzheimer`s disease. it is a chronic and progressive disease, and mostly afflicts elderlies. pd starts with sudden onsets and the exact cause of the disease is still unknown, however there are some early symptoms that can help us to diagnose the disease and ameliorate its effects. pd is a multi-factorial disease...

Parkinson`s disease (PD) is the second most common neurodegenerative disorder after Alzheimer`s disease. It is a chronic and progressive disease, and mostly afflicts elderlies. PD starts with sudden onsets and the exact cause of the disease is still unknown, however there are some early symptoms that can help us to diagnose the disease and ameliorate its effects. PD is a multi-factorial disease...

background outer membrane protein d (pd) is a highly conserved and stable protein in the outer membrane of both encapsulated (typeable) and non-capsulated (non-typeable) strains of haemophilus influenzae. as an immunogen, pd is a potential candidate vaccine against non-typeable h. influenzae (nthi) strains. objectives the aim of this study was to determine the cytokine pattern and the opsonic a...

Anti-PD-1/PD-L1 antibodies have been proved one of the most promising treatments against non-small cell lung cancer (NSCLC); however, whether anti-PD-1/PD-L1 antibodies can provide added benefits for pretreated patients with advanced NSCLC and which patients are most likely to benefit from anti-PD-1/PD-L1 therapy remain controversial. This meta-analysis evaluated the efficacy and safety between...

Abstract Objectives Checkpoint inhibitor (CPI)–associated colitis can limit therapy and has resemblance to inflammatory bowel disease (IBD). Studies exploring mechanistic similarities between these colitides are limited, yet therapeutic targets for either disorder could emerge from shared pathophysiology. Methods The morphology content of colonic biopsy specimens anti–CTLA-4 anti–PD-1/PD-L1 ant...

The anti-PD-1/PD-L1 therapy has been demonstrated effective and safe for advanced NSCLC patients, especially for EGFR-TKIs (epidermal growth factor receptor - tyrosine kinase inhibitors) resistant NSCLC (non-small cell lung cancer) patients with EGFR mutations. However, whether the anti-PD-1/PD-L1 therapy also promotes drug resistance as EGFR-TKIs treatment remains unclear. Thus, we conducted t...

BACKGROUND Anti-PD-1/PD-L1 antibody therapy is a promising clinical treatment for nonsmall-cell lung cancer (NSCLC). However, whether anti-PD-1/PD-L1 antibody therapy can provide added benefits for heavily pretreated patients with advanced NSCLC and whether the efficacy of anti-PD-1/PD-L1 antibody therapy relates to the tumor PD-L1 expression level remain controversial. Thus, this meta-analysis...

Background: Programmed cell death protein-1 (PD-1)/PD-L1 pathway is one of the immune checkpoint pathways involved in regulation of the immune responses and suppression of anti-tumor defense. PD-1/B7-H1-blocking antibodies improve immune responses such as cytotoxic activity of CD8+/CD4+T cells and also increase mortality of tumor cells; however their use is accompanied by adverse effects in pat...